SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is trending as retail and institutional investors capitalize on a high-velocity short squeeze fueled by massive short interest and intense anticipation of pivotal REGAL trial data. The community is actively debating the significance of the trial's longevity, the potential for a transformative buyout, and the impact of the drug's novel immunological design, while monitoring a rapid surge in volume that continues to pressure heavily shorted positions.

AeroVironment, Inc. is a defense technology company delivering integrated capabilities across air, land, sea, space, and cyber. The company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities-built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is seeing significant price volatility and heightened community interest following a series of new military contract announcements and reported government initiatives to increase drone production capacity. Investors are actively debating the company's long-term defense backlog and integration progress against broader sector concerns regarding potential valuation corrections and competition in the tactical drone space.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending as investors rotate into the stock as a defensive safe haven amid broader market volatility, with community interest amplified by its aggressive expansion into the streaming advertising space through the Vibe.co acquisition. While the stock has faced near-term pressure from concerns over consumer spending and insider selling, many are focused on its core supply chain efficiency and potential for sustained growth.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is gaining investor attention following a strategic decision to discontinue internal discovery programs and close its Alabama research facility, a move aimed at prioritizing external innovation and increasing long-term capital efficiency. Community discourse is heavily focused on the potential that these operational adjustments are a deliberate step to streamline the company for a future buyout, amid ongoing speculation regarding the value of its HAE portfolio.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the market reacts to the announcement of an upcoming FDA Advisory Committee meeting for its DMD therapy, deramiocel, sparking debate over whether this represents a routine regulatory step or an additional hurdle. While the community remains divided over the implications of the meeting, many investors are focused on the company's recent positive long-term clinical data and are using the temporary price volatility as an opportunity to accumulate shares ahead of the potential August approval.

Jack in the Box, Inc. engages in the provision of developing, operating, and franchising a chain of quick-service and fast-casual restaurants. It operates through the Jack in the Box and Del Taco segments. The Jack in the Box segment offers a selection of distinctive products including classic burgers and other product lines such as Buttery Jack Burgers. The company was founded by Robert Oscar Peterson in 1951 and is headquartered in San Diego, CA.

Jack In The Box, Inc.

Jack In The Box is experiencing significant market volatility as investors weigh the company's decision to divest Del Taco against intense short-interest concerns. The community remains deeply divided, with bulls pointing to potential turnaround plays and short-squeeze opportunities, while bears express significant skepticism regarding the company's debt levels and long-term viability.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is seeing intense investor focus as the stock navigates a pivotal commercial phase marked by robust revenue guidance, expanded dialysis adoption, and ongoing institutional efforts to secure favorable reimbursement legislation like K-CAPA. Community sentiment remains sharply divided, with longs highlighting the company's strong cash position and pipeline expansion, while vocal bears express frustration over price volatility and the ongoing transition from transitional add-on payments.

Applied Materials, Inc. engages in provision of materials engineering solutions used to produce semiconductors. The firm also focuses on design, development, production, and servicing of the critical wafer fabrication tools used for customers to manufacture semiconductors. It operates through the following segments: Semiconductor Systems and Applied Global Services (AGS). The Semiconductor Systems segment includes designing, development, manufacturing and sale of equipment used to fabricate semiconductor chips referred to as integrated circuits. The AGS segment engages in provision of services, spares, and factory automation software to customer fabrication plants globally. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

Applied Materials is trending as analysts aggressively hike price targets following a robust earnings report that highlighted record revenue and increased growth expectations fueled by the AI infrastructure boom. While retail investors are actively debating whether to buy the dip or lock in profits amid high volatility, the community is focused on the company's long-term strategic role in the semiconductor supply chain and the durability of its order visibility.

KLA Corp. engages in the supply of process control and yield management solutions for the semiconductor and related nano-electronics industries. The company operates through the following segments: Semiconductor Process Control, Specialty Semiconductor Process, and PCB, Display and Component Inspection. The Semiconductor Process Control segment provides a comprehensive portfolio of inspection, metrology and data analytics products and related services. The Specialty Semiconductor Process segment develops and sells advanced vacuum deposition and etching process tools. The PCB, Display and Component Inspection segment enables electronic device manufacturers to inspect, test and measure PCBs, flat panel displays and ICs to verify their quality. Its products include manufactured chips, reticle, packaging, surface profilers, nanochemical testers, KT pro equipment, and compound semiconductors. The company was founded on July 9, 1975 and is headquartered in Milpitas, CA.

KLA Corp.

KLA Corp. is experiencing significant market interest driven by its critical role in the semiconductor AI infrastructure buildout, with recent analyst upgrades reflecting a durable, long-term industry upcycle. Community discourse remains highly active, with traders closely monitoring its technical performance and potential for continued volatility as the stock hits new valuation benchmarks.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Himax Technologies is trending as investors aggressively re-price the stock following robust earnings guidance and growing excitement over its role in the TSMC-led Co-Packaged Optics (CPO) ecosystem. The community is focused on the company's strategic positioning within critical AI infrastructure supply chains and its potential as an enabler for next-generation AR and automotive display technologies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Memory Revenues to Nearly Triple in 2026: Semiconductor ETFs to Buy

 Semiconductor ETFs like SOXX offer broad exposure as AI-driven memory revenues are projected to nearly triple in 2026.

Should You Invest in the VanEck Fabless Semiconductor ETF (SMHX)?

QCOM Stock Gains: Qualcomm Doubles Down On Shareholder Returns Amid Growth Concerns

Equity

The company’s Board of Directors approved raising the quarterly cash dividend from $0.89 to $0.92 per share.


Nvidia CEO Jensen Huang Frames AI As ‘Foundational Infrastructure’ Ahead Of GTC Event Next Week

The remarks come ahead of Nvidia’s GTC conference next week, where investors expect updates on AI chip demand and supply constraints. 


 ETFs to Buy as NVIDIA Shares Gain Following Q4 Earnings Beat 

NVDA jumps after crushing Q4 earnings and strong guidance, lifting ETF plays like SMH tied to the AI chip leader. 

Nvidia Gets Backing From DA Davidson, JPMorgan Ahead Of Q4 Earnings And AI Growth Surge

Qualcomm Slides as Weak Q2 Outlook And Memory Market Headwinds Trigger Analyst Downgrades, Price Target Revisions

JPMorgan analyst Samik Chatterjee trimmed the 12-month price target for Qualcomm to $185 from $195 while retaining an ‘Overweight’ rating, citing challenges in the wider smartphone industry amid tightening DRAM availability. 

What Does The Street Think About The CoreWeave, Nvidia Deal?

Jefferies said that Nvidia's support on land and powered shells should ease execution risk and help scaling, according to TheFly. 

CRWV Stock Soars 10% Pre-Market As Nvidia Invests $2B To Expand AI Factory Network

The partnership aims to accelerate the development of more than 5 gigawatts of AI factories by 2030.


VanEck Announces Year-End Distributions for VanEck Equity ETFs

VanEck announced today the following 2025 annual distributions per share for its VanEck equity exchange-traded funds. Distributions Per Share for the VanEck ETFs Listed Below Ex-Date: December 22...

VanEck ETF Trust - VanEck Fabless Semiconductor ETF

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$61.80
Prev Close	$59.77
Open	$60.51
Dividend Yield	N/A
50-Day Moving Average	$57.40
Beta	N/A
Avg. Volume	115,757.30
PE Ratio	N/A

52-Week High	$68.36
52-Week Low	$30.44
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

SMHXVanEck Fabless Semiconductor ETF

Latest SMHX News